Incretin‐based therapies including liraglutide, semaglutide (GLP‐1 receptor agonists) and tirzepatide (GLP‐1/GIP agonist) have been licensed for managing T2D and obesity without diabetes alongside lifestyle modification.14, 15, 16. Here, GLP1R is linked to Obesity.